Core Insights - DaVita is making significant progress in value-based kidney care, demonstrating improved outcomes for patients with kidney disease through coordinated care models and partnerships with major insurers [2][3][4]. Group 1: Value-Based Care Progress - DaVita has invested in care innovation for over two decades, focusing on value-based models that provide comprehensive, longitudinal care rather than episodic treatment [3][6]. - The Comprehensive Kidney Care Contracting (CKCC) option within CMMI's Kidney Care Choices model shows year-over-year improvements, indicating the model's maturation and effectiveness [4][5]. - Patients involved in CKCC and related programs are experiencing better health outcomes due to enhanced care coordination and collaboration among healthcare teams [5][8]. Group 2: Financial and Operational Metrics - DaVita manages over $5 billion in medical costs under value-based care arrangements, which are linked to higher transplant rates and improved patient understanding of their conditions [6][7]. - The company has achieved over $200 million in shared savings since the inception of the program, reflecting its efficiency and effectiveness in care delivery [7]. - DaVita's Total Quality Score improved by 9%, driven by better treatment starts and patient engagement, alongside reduced missed treatments and lower rates of central venous catheter use [7]. Group 3: Long-Term Sustainability and Innovation - DaVita's integrated kidney care programs are showing signs of financial sustainability while also improving patient outcomes, suggesting a model that could be replicated for other chronic conditions [8]. - The company emphasizes the importance of continued investment in coordinated care to drive healthcare innovation and improve patient experiences [8].

During the year, we also outsourced our clinical trials operations, allowing our physicians and care teams to remain focused on delivering high-quality clinical care while still being able to direct our patients to the trials they need in our clinics and supporting more rapid growth and multi-market scalability. And finally, we strengthened our balance sheet during the year. We reduced debt on our convertible preferred note by $24 million and ended the year with $33.6 million in cash after experiencing posi ...

Financial Data and Key Metrics Changes - The Oncology Institute achieved a revenue increase of approximately 28% year-over-year, surpassing $500 million for the first time in its history, with total revenue for Q4 2025 reaching $142 million, a 41.6% year-over-year growth [5][20] - Adjusted EBITDA for Q4 2025 was $147,000, improving from a loss of $7.8 million in Q4 2024, marking the first profitable quarter from an adjusted EBITDA perspective as a public company [4][24] - SG&A expenses decreased by 2% year-over-year, reflecting operational efficiency, with SG&A as a percentage of revenue dropping from 24.8% to 19.7% [7][23] Business Line Data and Key Metrics Changes - The fee-for-service business grew 9% year-over-year from $136.2 million to $148.5 million, while the capitation business grew 17.2% year-over-year from $68.7 million to $80.5 million [17] - Pharmacy revenue grew 49.6% year-over-year from $179.9 million to $269.2 million, driven by improved prescription attachment rates [18] Market Data and Key Metrics Changes - The company expanded its capitated care model, initiating 9 new capitated contracts in California, Florida, and Nevada, adding approximately 260,000 patient lives under management [5][8] - The Florida Oncology Network platform grew to approximately 207 participating providers, supporting a hybrid model of patient care [10] Company Strategy and Development Direction - The Oncology Institute aims to continue scaling its value-based care platform, with a focus on expanding payer partnerships and achieving sustainable profitability [11][13] - The company plans to launch a proprietary network portal in Q2 2026 to enhance provider engagement and improve operational efficiencies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year positive adjusted EBITDA in 2026, driven by strong growth in the delegated capitation model [4][11] - The impact of the Inflation Reduction Act on the company's revenue is expected to be minor, with management indicating multiple strategies to offset any potential negative effects [15][16] Other Important Information - The company reduced debt on its convertible preferred note by $24 million, ending the year with $33.6 million in cash [8] - The leadership team was strengthened with new appointments, enhancing the company's ability to scale and execute its growth strategy [10][12] Q&A Session Summary Question: What drove the higher dispensing revenue in the quarter? - Management attributed the strong performance to operational execution in mitigating prescription leakage and strong patient encounter growth related to capitated contracts [30][31] Question: Will the Elevance contract size double in Florida in 2026? - Yes, that is the goal [32] Question: What is the size of the total addressable market for Elevance or Humana? - There is significant opportunity for growth, with many multiples of current capitated revenue available in Florida [34][35] Question: How are margins looking for capitated revenue? - Performance in terms of volume and medical loss ratio (MLR) is as expected, with no surprises [36] Question: Will SG&A improve in 2026? - Improvements are expected, but not to the same degree as in 2025 due to growth investments [65]

Financial Data and Key Metrics Changes - The Oncology Institute achieved its first profitable quarter as a public company from an adjusted EBITDA perspective in Q4 2025, with a revenue increase of approximately 28% year-over-year, surpassing $500 million for the first time [4][5] - Total revenue for Q4 2025 was $142 million, representing a 41.6% year-over-year growth, driven by patient growth and pharmacy contributions [20] - Adjusted EBITDA was $147,000 in Q4 2025, improving from -$7.8 million in Q4 2024 [24] Business Line Data and Key Metrics Changes - The fee-for-service business grew 9% year-over-year from $136.2 million to $148.5 million, while the capitation business grew 17.2% year-over-year from $68.7 million to $80.5 million [17] - Pharmacy revenue grew 49.6% year-over-year from $179.9 million to $269.2 million, primarily due to improved prescription attachment rates [18] Market Data and Key Metrics Changes - The company expanded its capitated footprint by initiating 9 new capitated contracts during 2025, adding approximately 260,000 patient lives under management [5] - The partnership with Elevance Health in Florida ramped up, with approximately 70,000 lives under capitated arrangements by the end of 2025 [8] Company Strategy and Development Direction - The Oncology Institute aims to continue scaling its value-based care platform and expects over 80% growth in capitated revenue for 2026 [11] - The company plans to launch a proprietary new network portal in Q2 2026 to enhance engagement with providers and improve operational efficiencies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow and manage industry-leading medical loss ratio (MLR) performance under its delegated capitation model [13] - The company views the potential lower rate environment for Medicare Advantage as a tailwind, as it allows for proactive engagement with payers seeking to improve care delivery [74] Other Important Information - The company reduced debt on its convertible preferred note by $24 million and ended the year with $33.6 million in cash [8] - The leadership team was strengthened with new appointments, including a Chief Clinical Officer and a Chief Administrative Officer [10] Q&A Session Summary Question: What drove the higher dispensing revenue in Q4? - The strong performance was driven by operational execution in mitigating leakage of prescriptions and strong patient encounter growth related to capitated contract growth [31] Question: Will the Elevance contract double in size in 2026? - Yes, that is the goal [32] Question: What is the size of the total addressable market for Elevance or Humana? - There is significant opportunity for growth, with many multiples of current capitated revenue available in the market [35] Question: Will there be a dip in profit margins due to ramping up capitated contracts? - A slight increase in MLR is expected for delegated contracts, but overall gross margins should not dip [44] Question: Can you provide details on the number of affiliated clinics? - The network has grown to over 200 providers in Florida, bringing the total to close to 300 combined [46] Question: What are the expectations for SG&A in 2026? - Improvements in SG&A as a percentage of revenue are expected, but not to the same degree as in 2025 due to growth investments [65]

Core Insights - Alignment Healthcare focuses on delivering high-quality care at a low cost, avoiding aggressive coding practices and financial engineering, which has allowed the company to navigate industry volatility while achieving growth and improving profitability [3][2][1] Strategy and Market Position - The company emphasizes a care model that can scale, supported by a technology platform that enables daily operational oversight and prioritizes durable membership growth over volume [2][6] - Alignment is expanding successfully beyond California, with notable membership and high Star Ratings in Nevada, Texas, Arizona, and North Carolina, while maintaining a disciplined capital structure [4][13] Growth Metrics - Management reported a 31% year-over-year membership growth, primarily driven by retention improvements, with a disenrollment rate down to approximately 6% and switchers accounting for about 83% of growth [5][7] - The company has set a public target of at least 20% growth moving forward, with a positive outlook for opportunities in 2027 [8] Medical Loss Ratio (MLR) Management - New-member MLRs are expected to improve from the high 80s/low 90s into the mid-80s as cohorts mature, despite absorbing V28 adjustments [10][9] - The company has been accurate in predicting costs for loyal members, with no notable surprises in early-year payment visibility [9] Care Model and Member Engagement - The Care Anywhere program currently engages about 65% of members, targeting those who account for a significant portion of healthcare spending, with plans to increase engagement to 75%-80% over time [11][12] - Alignment utilizes a unified data architecture to provide actionable data, allowing for quick intervention in utilization or costs [12] Provider Relationships and Compensation - The company seeks financial, operational, and clinical alignment with providers, typically paying hospitals and specialists at 100% of Medicare fee-for-service, with a preference for guaranteed monthly payments for primary care physicians [15][16] Capital Structure and Financial Outlook - Alignment has established an undrawn revolving credit facility to strengthen its capital structure as it transitions to profitability in 2025, providing low-cost access to liquidity if needed [18] - The company anticipates an uptick in the upcoming CMS rate-setting process, with expectations of a 2%-3% net adjustment [17]

Core Viewpoint - DocGo is positioning itself as a leader in mobile healthcare and medical transportation, targeting a revenue of $280 million to $300 million by 2026, excluding COVID-related and asylum/migrant work, focusing on its core medical transportation and mobile healthcare services [1][6]. Business Operations - In 2025, DocGo conducted over 700,000 patient transports, completed 150,000 in-home patient visits, remotely monitored approximately 55,000 patients, and performed over 1 million telehealth visits [2]. - The company operates nearly 1,000 vehicles and employs more than 3,000 clinical staff, having served over 10 million patients since its inception [2]. Strategic Positioning - DocGo aims to deliver "proactive healthcare at any address," improving access and reducing unnecessary emergency department utilization, addressing healthcare system capacity constraints and rising chronic diseases [3]. - The company is expanding its mobile health footprint to close care gaps and pursue value-based care, bolstered by the acquisition of SteadyMD, which contributed over $25 million in revenue and more than 1 million telehealth visits [4]. Revenue and Financial Guidance - Medical transportation is projected to generate over $200 million in revenue this year, supported by significant operational scale [5]. - DocGo guided for an adjusted EBITDA loss of $15 million to $25 million, expecting to exit the year at a break-even run rate, with approximately $95 million in cash and no outstanding debt as of Q3 [6][7]. Customer Relationships - The company collaborates with large health systems and major insurance payers, relying on referrals rather than direct-to-consumer marketing [8]. - DocGo has established relationships with hospital systems such as Northwell and Mount Sinai, and payers including Molina and Anthem, achieving a patient Net Promoter Score above 92 [9]. Mobile Health Services - DocGo performs over 40 different types of care gap services in-home, including diabetic checks and wellness visits, aiming to bring the capabilities of a doctor's office into patients' homes [12]. - The operational model pairs clinicians with remote advanced providers to maximize efficiency and address social determinants of health [13]. Technology Integration - The company has developed an "Uber-like" logistics platform integrated with Epic, enhancing transparency and coordination in medical transportation [15][16]. - DocGo's technology is designed to optimize field efficiency by matching clinicians, vehicles, and patient needs, providing precise arrival windows [16]. Long-term Opportunities - The company believes it is well-positioned for value-based arrangements due to its home-based operations and remote patient monitoring capabilities [18]. - Bienstock highlighted the importance of scaling medical transportation and the potential benefits from CMS programs rewarding better health outcomes [18].

Core Insights - Humana has announced new partnerships to enhance heart health for eligible Medicare Advantage members through value-based care, expanding its existing cardiac care program [1] Group 1: Partnerships and Services - New partnerships include collaborations with Karoo Health, US Heart and Vascular, and Chamber Cardio, building on the existing relationship with CVAUSA's Novocardia Care Solutions [1] - Enhanced cardiac care services will be available to eligible Humana Medicare Advantage members, focusing on integrated, coordinated, and evidence-based care [1] Group 2: Key Features of the Program - Integrated team support will involve care management teams and cardiologists working together on personalized care plans [1] - Remote monitoring tools will be utilized to track heart rate, rhythm, and blood pressure, allowing for timely adjustments [1] - A 24/7 hotline will provide members with round-the-clock access to coordinated care teams [1] - Value-based care teams will emphasize proactive care to improve health outcomes and reduce unnecessary emergency visits [1] Group 3: Geographic Availability - Services will be available in multiple states, including Alabama, Arizona, Louisiana, Texas, Kansas, Maryland, Georgia, South Carolina, North Carolina, Virginia, Washington, DC, Illinois, Mississippi, and Iowa [1] Group 4: Company Commitment - Humana is committed to expanding access to high-quality, whole-person care, aiming for better health outcomes through value-based care [1]

Summary of Agilon Health FY Conference Call (March 02, 2026) Company Overview - **Company**: Agilon Health (NYSE: AGL) - **Industry**: Healthcare Services - **Business Model**: Partnering with physician groups and health systems to support approximately 2,200 primary care physicians (PCPs) and over 500,000 Medicare Advantage (MA) members in transitioning to value-based care through a specialized platform and operational support [1][1]. Key Financial Highlights - **Fourth Quarter Results**: Cost trends increased year-over-year from mid-5% to 6.5%, driven by unique inpatient cases totaling over $6.5 million [4][4]. - **2026 EBITDA Guidance**: Aiming for break-even EBITDA, supported by: - Effective growth rate benchmark of over 9% [5][5]. - Disciplined contracting approach, impacting 80% of contracts, resulting in $125 million medical margin improvement year-over-year [6][6]. - Anticipated 40 basis points improvement in risk adjustment due to clinical pathways implemented, particularly in heart failure [7][7][8][8]. - Administrative cost improvements of $35 million [9][9]. Cost Trends and Challenges - **Inpatient and Part B Costs**: Notable increases in costs, particularly in oncology, with trends in the 10% range over the past 15-18 months [11][12]. - **Future Cost Projections**: For 2026, a gross cost trend of 7.5% and a net cost trend of 7% are anticipated, reflecting ongoing elevated cost trends [13][14]. Data and Risk Management - **Data Pipeline**: Enhanced capabilities for calculating member-level risk scores, with 85% of members on the new data pipeline, improving visibility into medical expenses and cost trends [16][17][18][18]. - **Cash Position**: Ended 2025 with a cash balance of $125 million, improved from a previous estimate of $100 million, providing flexibility for 2026 operations [20][21]. Market Dynamics and Enrollment Trends - **Medicare Advantage Enrollment**: Observed low single-digit growth, indicating potential structural slowing in the market, but long-term growth in Medicare is expected due to demographic trends [28][29]. - **Payer Relationships**: Positive partnerships with payers, with increased financial incentives for superior quality performance, reflecting a constructive negotiation environment [43][44]. Clinical Programs and Operational Efficiency - **Clinical Pathways**: Expansion of clinical programs, including COPD and dementia, alongside the existing heart failure program, aimed at reducing costs and improving patient outcomes [36][37]. - **Cost Management**: Ongoing efforts to right-size the cost structure in response to membership changes, with a focus on leveraging AI for operational efficiencies [37][38]. Future Outlook - **Transformational Path**: The company is on a path of transformation, with significant progress made in 2025 and ongoing initiatives to enhance profitability in 2026 and beyond [51][51]. - **CEO Search**: The board is actively engaged in a thorough search process for a new CEO, with both internal and external candidates being considered [50][50]. This summary encapsulates the key points discussed during the Agilon Health FY Conference Call, highlighting the company's financial performance, market dynamics, operational strategies, and future outlook.

Core Insights - The company reported significant year-over-year growth in profitability, with adjusted EBITDA rising to $110 million in 2025 from approximately breakeven in 2024, reflecting a margin expansion of 270 basis points [1][7] - Total revenue for 2025 reached $3.9 billion, marking a 46% increase year-over-year, driven by a 25% growth in membership [2][7] - The company exceeded guidance across profitability metrics, with adjusted gross profit of $125 million and an adjusted medical benefit ratio (MBR) of 87.7% in Q4 2025 [3][5] Financial Performance - For Q4 2025, health plan membership totaled 236,300, representing a 25% year-over-year growth, and total revenue for the quarter was $1.0 billion, up 44% year-over-year [4][7] - Adjusted gross profit for the full year was $495 million, resulting in an MBR of 87.5%, an improvement of 130 basis points year-over-year [2][7] - Full-year 2026 guidance includes membership growth to 292,000–298,000, revenue of $5.14–5.19 billion, and adjusted EBITDA of $133–163 million [18] Membership and Market Expansion - Membership reached 275,300 in January 2026, reflecting a 31% year-over-year growth, with significant growth in both California (23%) and ex-California counties (over 80%) [11][7] - The company demonstrated the replicability of its model outside California, with membership outside the state more than doubling to approximately 38,000, representing about 16% of total membership [6][9] Operational Efficiency - The company generated positive free cash flow in 2025 and ended the year with $604 million in cash and investments, alongside a $200 million revolving credit facility [6][17] - Adjusted SG&A expenses increased by 28% year-over-year to $385 million, but as a percentage of revenue, it improved to 9.7% from 11.1% in 2024, a decline of about 140 basis points [8][7] Strategic Outlook - The company plans to invest in sales and distribution, deepen broker relationships, and continue growing with aligned provider partners, viewing its less than 4% market share in 23 counties outside California as an opportunity for growth [10][7] - Management emphasized a responsible approach to growth, with nearly 20% improvement in voluntary disenrollment metrics and sourcing about 80% of gross sales from plan switchers [12][7]

Core Insights - Agilon Health is undergoing a comprehensive transformation aimed at sustainable performance, with a focus on operational discipline and clinical pathways [2][3] - The company anticipates significant improvements in profitability for 2026, driven by disciplined contracting and clinical initiatives [3][6] Financial Performance - For full-year 2025, Agilon reported an adjusted EBITDA of -$296 million and a medical margin of -$57 million, with elevated medical cost trends of approximately 6.5% for the year [5][9] - Revenue for 2025 was $5.93 billion, with Q4 revenue at $1.57 billion, impacted by lower-than-expected risk adjustment revenue and market exits [7][8] Membership and Growth - Year-end 2025 Medicare Advantage membership was 511,000, with ACO REACH membership at 114,000, influenced by a measured growth approach and market exits [7][12] - For 2026, the company targets membership of approximately 525,000 to 540,000, including about 430,000 in Medicare Advantage [6][12] Cost Management and Projections - Management expects a medical margin of $300 million to $350 million and adjusted EBITDA ranging from -$15 million to +$15 million for 2026, with breakeven at the midpoint [6][17] - The company executed $35 million in additional operating cost reductions and anticipates G&A expenses of approximately $234 million for 2026 [4][19] Clinical and Operational Improvements - Agilon has expanded clinical pathways and improved its data pipeline, covering over 85% of members with a 99%+ correlation rate to enhance risk scoring [4][15] - The company emphasizes evidence-based care models for chronic conditions, with significant adoption of its heart failure program across its network [16] Regulatory and Market Outlook - Agilon is preparing for the 2027 Medicare Advantage Advance Notice, believing its risk model changes will align closely with national averages [1][20] - The company is also engaged in discussions regarding the new LEAD program, which is expected to launch after the REACH model concludes [21]